[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628711":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":38,"responsibleParty":53,"collaborators":26,"id":55,"slug":26,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":26,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":26,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":78,"whyStopped":26,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Biocells Medical","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MSC therapy","EXPERIMENTAL","200,000,000 cells per infusion",[13],"Drug: MSCs",{"label":15,"type":16,"description":17,"interventionNames":18},"Saline Solution","PLACEBO_COMPARATOR","0.9% saline infusion",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","MSCs","IV infusion of 200,000,000 of neuroinduced mesynchimal stem cells at week 1 of the trial period",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"OTHER","Placebo","Intravenous 0.9% saline infusion, volume- and appearance-matched",[15],[33],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Andrei Peskau, M.D.","CONTACT","+48660639936","info@biocellsmedical.com",[39],{"facility":40,"status":26,"city":41,"state":26,"zip":26,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"BioCells Medical","Warsaw","Poland","PL",{"type":45,"coordinates":46},"Point",[47,48],21.01178,52.22977,{"lat":48,"lon":47},[51],{"name":52,"role":35,"phone":36,"phoneExt":26,"email":37},"Miron Danielevich, PhD",{"type":54,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100628711",false,"NCT07465198","Autologous Stem Cell Therapy in Patients With Multiple System Atrophy","A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Autologous Stem Cell Therapy in Patients With Multiple System Atrophy","Inclusion Criteria:\n\n* Multiple System Atrophy (MSA-P or MSA-C)\n* Age range of 35 to 65 years\n\nExclusion Criteria:\n\n* Other major neurological disorders\n* Severe cardiac\u002Frenal\u002Fhepatic impairment\n* Prior stem cell therapy","ALL","35 Years","65 Years",{"count":65,"type":66},50,"ESTIMATED","INTERVENTIONAL",[69],"PHASE2","This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo\u002Fcontrolled group.",[72,73],"MSA - Multiple System Atrophy","MSA",[73,75,76,77],"Multiple System Atrophy","MSC","Mesenchimal stem cells","NOT_YET_RECRUITING","2026-03-09",{"date":81,"type":82},"2026-03-11","ACTUAL",{"date":84,"type":66},"2026-09-01",{"date":86,"type":66},"2031-03-01",{"name":5,"class":6},1]